The FDA approved the RET selective inhibitor, such as selpercatinib (LOXO-292) and pralsetinib (BLU-667), as the standards of care for RET-rearrangement-involved advanced NSCLC (Lin et al., 2020). The gene discussed is RET; the disease is non-small cell lung carcinoma.